SCYNEXIS INC. - 10-Q Summary (Q2 2025)
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. SCYNEXIS, Inc. is a biotechnology company developing antifungal medicines, primarily focusing on its proprietary "fungerp" platform. Key assets include the FDA-approved drug BREXAFEMME (ibrexafungerp) and the clinical candidate SCY-247. The company operates as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | Balance Sheet (June 30, 2025) |
|---|---|---|---|
| Revenue | $1.36 million | $1.62 million | N/A |
| Net Loss | $(6.89) million | $(12.28) million | N/A |
| Operating Expenses | $10.93 million | $19.81 million | N/A |
| Cash & Investments | N/A | N/A | $46.5 million |
| Accumulated Deficit | N/A | N/A | $(388.8) million |
| Debt | N/A | N/A | $0 (Convertible debt repaid) |
Note: Revenue is derived entirely from the GSK License Agreement. The company reported a significant non-cash gain of $2.17 million in Q2 and $5.09 million YTD due to the fair value adjustment of warrant liabilities.
Material Changes vs. Prior Period
- Revenue: Q2 2025 revenue increased 85% to $1.36 million compared to $0.74 million in Q2 2024, driven by the recognition of a $10.0 million milestone receivable (billed but not yet collected) related to the resumption of the MARIO study.
- Net Loss: Net loss improved significantly in Q2 2025 ($6.89 million) compared to Q2 2024 ($14.46 million), primarily due to a $7.9 million swing in warrant liability fair value adjustments (gain in 2025 vs. loss in 2024).
- Debt: The company fully repaid its $14.0 million March 2019 convertible notes in March 2025, eliminating interest expense and amortization of debt issuance costs for the current period.
- Operating Expenses: R&D expenses increased slightly in Q2 ($7.14 million vs. $6.81 million) but decreased YTD ($12.28 million vs. $14.02 million) due to the completion of prior studies (FURI and CARES).
Outlook, Risks, and Contingencies
- GSK Dispute: A material contingency exists regarding the Phase 3 MARIO study. While the FDA lifted the clinical hold in April 2025 and SCYNEXIS resumed dosing (triggering a $10 million milestone billing), GSK notified the company of its intent to terminate the study unilaterally. SCYNEXIS disputes this right and is seeking to resolve the disagreement. Failure to resolve this could result in the reversal of the $10 million receivable and loss of future milestones.
- Liquidity: Management believes current capital resources ($46.5 million) are sufficient to fund operations for at least 12 months. However, future funding may be required via equity or debt offerings.
- Nasdaq Compliance: The company received a deficiency notice on June 20, 2025, for trading below the $1.00 minimum bid price for 30 consecutive days. It has 180 days (until December 17, 2025) to regain compliance to avoid potential delisting.
- Legal Proceedings: A securities class action lawsuit regarding manufacturing cross-contamination disclosures remains pending, though the court granted a motion to dismiss with leave to amend in July 2025. Shareholder derivative complaints are currently stayed.
Investor Verification Checklist
- GSK Milestone Collectibility: Verify the status of the $10.0 million receivable and the likelihood of GSK honoring the payment given the termination dispute.
- Warrant Liability Volatility: Assess the impact of stock price fluctuations on the non-cash warrant liability adjustments, which significantly distort net loss figures.
- Nasdaq Compliance Plan: Confirm the company's strategy to regain the $1.00 minimum bid price before the December 17, 2025 deadline.
- Cash Burn Rate: Monitor the net cash used in operating activities ($15.0 million YTD) against the $46.5 million cash balance to validate the 12-month runway estimate.
- SCY-247 Progress: Track the release of Phase 1 data for SCY-247, expected in Q3 2025, as a key driver for future valuation.